PARTNERING WITH JAPANESE PHARMA TO COMBAT NEGLECTED DISEASES

GHIT R&D Forum, Tokyo, Japan

December 8th, 2017

Peter Warner, DPhil, MA.
1994
Bill Gates Sr. starts a small philanthropic foundation at his son’s request.

1997
Bill and Melinda read an article about rotavirus and are inspired to act.

2000
The Bill & Melinda Gates Foundation is created, with a focus on health, education, and libraries.

2006
Warren Buffett pledges Berkshire Hathaway stock valued at $31 billion.

2008
Bill joins Melinda full-time at the foundation.

2011
The foundation moves to its new permanent home in Seattle.

2015
The foundation celebrates its 15-year anniversary.
THE SCOPE OF OUR WORK

We work with partner organizations around the world to reduce inequity

<table>
<thead>
<tr>
<th>Program Strategies</th>
<th>Value of Grants</th>
<th>Countries</th>
<th>Employees</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>$4.3B</td>
<td>158</td>
<td>1,453</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grantees</th>
<th>No. of Grants</th>
<th>U.S. States</th>
<th>Alumni</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,176</td>
<td>1,574</td>
<td>47</td>
<td>1,220</td>
</tr>
</tbody>
</table>

For the Year ended December 31, 2016. Amounts in thousands of U.S. dollars. Value of Grants total represents grants only.
Grantees and partners are at the center of our work

Together, we take risks, push for new solutions and harness the power of science and technology

This work requires support from governments, the private sector, communities, nonprofits and individuals
COMBAT INFECTIOUS DISEASES THAT PARTICULARLY AFFECT THE POOR

We believe we can save lives by delivering the latest in science and technology to those with the greatest needs.

Select examples of this work:
- Accelerate progress to eradicate malaria
- Reduce HIV infections and extend lives of people with HIV
- Deliver life-saving vaccines where they’re needed most
- Work to eradicate polio
HOW WE WORK: CROSS-CUTTING FUNCTIONS
TB DRUG ACCELERATOR – AN EXAMPLE OF DRUG DISCOVERY COLLABORATION

Company Compound Libraries \rightarrow Collaborative Discovery Research \rightarrow Lead Optimization \rightarrow Multiple Candidates, Advance Regimen to Proof of Concept

Target Identification

Hit Generation

PHARMACEUTICAL COMPANIES:

- Bayer
- Lilly
- Eisai
- AstraZeneca
- MERCK
- SANOFI
- abbvie
- gsk

RESEARCH INSTITUTIONS:

- NIH
- National Institute of Allergy and Infectious Diseases
- Rutgers Biomedical and Health Sciences
- IDRI
- Colorado State University
- TB ALLIANCE
- Global Alliance for TB Drug Development
- Bill & Melinda Gates Foundation
Japan has a long and highly successful track record of innovation in drug discovery

Antibiotic drug development has been a particular strength

The Global Health Innovative Technology Fund provides a unique mechanism to bring assets from Pharma companies in Japan to bear on Neglected Diseases

The BMGF thanks all the Japanese funders and participating companies for joining with us in our mission to deliver new drugs and vaccines to combat disease that particular afflict the poor.

We look forward to working with Japanese partners to deliver new drugs and vaccines that will impact on neglected diseases.